Olympus Medical Systems failed to submit timely Medical Device Reports for endoscope malfunctions, FDA says.
What happened
FDA inspected Olympus Medical Systems in Hachioji-shi, Tokyo, Japan, from September 6 to September 9, 2022. FDA found the company did not submit Medical Device Reports (MDRs) within 30 calendar days for complaints showing its Uretero-Reno Fiberscope and Uretero-Reno Videoscope broke or ruptured during use. The company responded on September 30, 2022, saying corrective actions were still ongoing.
What FDA found
Olympus did not submit a Medical Device Report to FDA within 30 calendar days after learning of a device malfunction that could likely cause or contribute to death or serious injury if it recurred.
21 CFR 803.50(a)(2)FDA said the endoscopes were misbranded because the firm failed to furnish required information under section 519 of the Act.
section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2); section 519, 21 U.S.C. § 360i
What FDA wants
FDA asks Olympus to notify it in writing within 15 business days of steps taken to correct the violation and prevent recurrence. FDA also asks for documentation when corrective actions are complete, including a revised MDR procedure and a retrospective review of complaints for reportability.
Who should pay attention
- hospitals and endoscopy units using Olympus scopes
- distributors and importers of Olympus medical devices
- device quality teams responsible for MDR reporting
This is a summary. Read the original letter on fda.gov.